APRE (Aprea Therapeutics) Insider Ownership : 22.78 % (As of Dec. 12, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aprea Therapeutics's insider ownership is 22.78%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aprea Therapeutics's Institutional Ownership is 36.96%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aprea Therapeutics's Float Percentage Of Total Shares Outstanding is 74.15%.

Aprea Therapeutics Insider Ownership Historical Data

The historical data trend for Aprea Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics Insider Ownership Chart

Aprea Therapeutics Historical Data

The historical data trend for Aprea Therapeutics can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Insider Ownership	31.10	31.82	21.90	22.02	22.13	22.13	22.13	22.13	22.79	22.78

Aprea Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Aprea Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

3805 Old Easton Road, Doylestown, PA, USA, 18902

Website

https://www.aprea.com

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Executives

Oren Gilad	officer: President, CEO	535 BOYLSTON STREET, BOSTON MA 02116
Marc Duey	director	27 STRATHMORE ROAD, NATICK MA 01760
Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
John P. Hamill	officer: SrVP/CFO/Prin. Fin &Acctg. Off	4092 NEW HOPE ROAD, FURLONG PA 18925
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Grissinger	director	C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Rifat Pamukcu	director	535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade	director, officer: President & CEO	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar	officer: SVP, Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel	officer: Chief Business Officer	535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen	officer: SVP, Chief Scientific Officer	535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129